Related Experiment Videos
Intermittent androgen suppression. Too good to be true?
1Department of Urology, Lund University Hospital, University of Lund, Sweden. per-anders.abrahamsson@urokir.lu.se
Scandinavian Journal of Urology and Nephrology. Supplementum
|January 15, 2000
Summary
Intermittent androgen suppression therapy offers a promising new approach for metastatic prostate cancer that becomes resistant to standard treatments. This method may preserve androgen sensitivity, unlike continuous androgen deprivation, showing favorable results in early studies.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic prostate cancer can progress to an androgen-independent state, limiting treatment options.
- Current androgen deprivation therapies can lead to loss of androgen sensitivity.
Purpose of the Study:
- To explore intermittent androgen suppression therapy as an alternative treatment for advanced prostate cancer.
- To evaluate if this intermittent approach can maintain androgen sensitivity.
Main Methods:
- Adaptation of existing androgen ablation techniques.
- Pilot studies comparing intermittent vs. continuous androgen suppression.
Main Results:
- Intermittent androgen suppression therapy shows promise in early investigations.
- This approach favorably compares with continuous androgen deprivation in pilot studies.
Conclusions:
- Intermittent androgen suppression therapy is a potentially excellent treatment for advanced prostate cancer.
- Further clinical studies are necessary to confirm efficacy and optimal use, individually or in combination.